ArticleFrontiers in physiology2026
Interleukin-13 R130Q aggravates airway smooth-muscle phenotypic switching and promotes airway remodeling in severe asthma.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Airway remodeling represents a key pathological feature of severe asthma. Although the interleukin-13 (IL-13) R130Q variant is associated with increased disease severity, its specific contribution to airway remodeling remains unclear. Methods: This study used an ovalbumin (OVA)-induced asthma model in which mice were sensitized intraperitoneally with OVA/alum and subsequently challenged intranasally with OVA; human IL-13 130R or IL-13 130Q was administered intranasally before each challenge. Primary human bronchial smooth muscle cells (hBSMCs) from a single healthy donor were treated with both variants to assess CCK-8-derived proliferative/metabolic activity, migration, acetylcholine (ACh)-induced intracellular calcium responses, and IL-4 and IL-5 concentrations in culture supernatants. JAK2 and STAT6 phosphorylation was evaluated separately as a downstream signaling readout. Structural modeling and independent triplicate 100-ns molecular dynamics simulations of the IL-13/IL-13 receptor alpha 2 (IL-13Rα2) complex were performed using GROMACS 2025.4 with the AMBER ff19SB force field, and molecular mechanics/generalized Born surface area analysis was used for relative comparison of binding free energies. Results: IL-13 130Q produced limited airway changes in mice without OVA sensitization, but exacerbated airway wall thickening, luminal narrowing, smooth-muscle expansion, and pulmonary inflammation in OVA-sensitized and intranasally challenged mice. In hBSMCs, IL-13 130Q induced greater CCK-8-derived proliferative/metabolic activity, migration, ACh-induced intracellular calcium responses, and IL-4 and IL-5 concentrations than IL-13 130R at 10 -100 ng/mL. Molecular dynamics analyses suggested the reduced binding stability of IL-13 130Q/IL-13Rα2 complex, as reflected by fewer interfacial hydrogen bonds, altered intermolecular contacts, and a less favorable relative binding free energy. Elevated JAK2/STAT6 phosphorylation indicated the amplification of downstream signaling, mechanistically tied to potential reduced decoy-receptor affinity. Conclusion: These preclinical data support a contextdependent potentiating function of IL13 130Q in airway smoothmuscle phenotypic modulation and airway remodeling. Further investigation may rationalize genotype-based stratification in the therapy of severe asthma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.